Von Hoff D D
Cancer Therapy and Research Center, and Department of Medicine, University of Texas Health Science Center at San Antonio, 78245, USA.
Clin Cancer Res. 1998 May;4(5):1079-86.
Unfortunately, the vast majority (90%) of new anticancer agents designed in the laboratory never make it into routine clinical use. The hypothesis of this lecture is that many new agents fail in the clinic because the appropriate clinical trial(s) that could exploit the attributes of the new agent are not performed. An appreciation that both bench and clinical investigations are difficult endeavors should aid in improving clinical trial designs and give the best chance for new agents to be added to our therapeutic armamentarium.
不幸的是，实验室设计的绝大多数（90%）新型抗癌药物从未进入常规临床应用。本次讲座的假设是，许多新型药物在临床中失败是因为没有开展能够利用其特性的适当临床试验。认识到基础研究和临床研究都是艰巨的工作，这将有助于改进临床试验设计，并为新型药物加入我们的治疗手段提供最佳机会。
